PARP Inhibitor-Resistant Ovarian Cancer Responds to PARP Plus ATR Inhibitors
Stephanie L. Wethington, MD, MSc, discusses results of a study of olaparib plus ceralasertib for overcoming resistance to PARP inhibition.